Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease by Baksh, Sheriza N, Segal, Jodi B, McAdams-DeMarco, Mara, Kalyani, Rita R, Alexander, G Caleb, Ehrhardt, Stephan

Get full text

Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis by Di Stefano, Leon, Ram, Malathi, Scharfstein, Daniel O, Li, Tianjing, Khanal, Preeti, Baksh, Sheriza N, McBee, Nichol, Bengtson, Charles D, Gadomski, Anne, Geriak, Matthew, Puskarich, Michael A, Salathe, Matthias A, Schutte, Aletta E, Tignanelli, Christopher J, Victory, Jennifer, Bierer, Barbara E, Hanley, Daniel F, Freilich, Daniel A

Get full text

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial by Baksh, Sheriza N, Heath, Sonya L, Fukuta, Yuriko, Shade, David, Meisenberg, Barry, Bloch, Evan M, Tobian, Aaron A R, Spivak, Emily S, Patel, Bela, Gerber, Jonathan, Raval, Jay S, Forthal, Donald, Paxton, James, Mosnaim, Giselle, Anjan, Shweta, Blair, Janis, Cachay, Edward, Currier, Judith, Das, Piyali, Huaman, Moises, Sutcliffe, Catherine, Yarava, Anusha, Casadevall, Arturo, Sullivan, David, Hanley, Daniel, Gebo, Kelly A

Get full text

Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: A disproportionality analysis among high‐risk patients by Baksh, Sheriza N., McAdams‐DeMarco, Mara, Segal, Jodi B., Alexander, G. Caleb

Get full text

Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis by Leon Di Stefano, Elizabeth L. Ogburn, Malathi Ram, Daniel O. Scharfstein, Tianjing Li, Preeti Khanal, Sheriza N. Baksh, Nichol McBee, Joshua Gruber, Marianne R. Gildea, Megan R. Clark, Neil A. Goldenberg, Yussef Bennani, Samuel M. Brown, Whitney R. Buckel, Meredith E. Clement, Mark J. Mulligan, Jane A. O’Halloran, Adriana M. Rauseo, Wesley H. Self, Matthew W. Semler, Todd Seto, Jason E. Stout, Robert J. Ulrich, Jennifer Victory, Barbara E. Bierer, Daniel F. Hanley, Daniel Freilich

Get full text

Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients by Baksh, Sheriza N., Gellad, Walid F., Alexander, G. Caleb

Get full text

Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis by Di Stefano, Leon, Ogburn, Elizabeth L, Ram, Malathi, Scharfstein, Daniel O, Li, Tianjing, Khanal, Preeti, Baksh, Sheriza N, McBee, Nichol, Gruber, Joshua, Gildea, Marianne R, Clark, Megan R, Goldenberg, Neil A, Bennani, Yussef, Brown, Samuel M, Buckel, Whitney R, Clement, Meredith E, Mulligan, Mark J, O'Halloran, Jane A, Rauseo, Adriana M, Self, Wesley H, Semler, Matthew W, Seto, Todd, Stout, Jason E, Ulrich, Robert J, Victory, Jennifer, Bierer, Barbara E, Hanley, Daniel F, Freilich, Daniel

Get full text

Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment by Karaba, Andrew H, Johnston, Trevor S, Beck, Evan, Laeyendecker, Oliver, Cox, Andrea L, Klein, Sabra L, Sullivan, David J

Get full text

Early antibody treatment, inflammation, and risk of post-COVID conditions by Gebo, Kelly A, Heath, Sonya L, Fukuta, Yuriko, Zhu, Xianming, Baksh, Sheriza, Abraham, Allison G, Habtehyimer, Feben, Shade, David, Ruff, Jessica, Ram, Malathi, Laeyendecker, Oliver, Fernandez, Reinaldo E, Patel, Eshan U, Baker, Owen R, Shoham, Shmuel, Cachay, Edward R, Currier, Judith S, Gerber, Jonathan M, Meisenberg, Barry, Forthal, Donald N, Hammitt, Laura L, Huaman, Moises A, Levine, Adam, Mosnaim, Giselle S, Patel, Bela, Paxton, James H, Raval, Jay S, Sutcliffe, Catherine G, Anjan, Shweta, Gniadek, Thomas, Kassaye, Seble, Blair, Janis E, Lane, Karen, McBee, Nichol A, Gawad, Amy L, Das, Piyali, Klein, Sabra L, Pekosz, Andrew, Bloch, Evan M, Hanley, Daniel, Casadevall, Arturo, Tobian, Aaron A R, Sullivan, David J

Get full text

Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions" by Gebo, Kelly A, Heath, Sonya L, Fukuta, Yuriko, Zhu, Xianming, Baksh, Sheriza, Abraham, Allison G, Habtehyimer, Feben, Shade, David, Ruff, Jessica, Ram, Malathi, Laeyendecker, Oliver, Fernandez, Reinaldo E, Patel, Eshan U, Baker, Owen R, Shoham, Shmuel, Cachay, Edward R, Currier, Judith S, Gerber, Jonathan M, Meisenberg, Barry, Forthal, Donald N, Hammitt, Laura L, Huaman, Moises A, Levine, Adam, Mosnaim, Giselle S, Patel, Bela, Paxton, James H, Raval, Jay S, Sutcliffe, Catherine G, Anjan, Shweta, Gniadek, Thomas, Kassaye, Seble, Blair, Janis E, Lane, Karen, McBee, Nichol A, Gawad, Amy L, Das, Piyali, Klein, Sabra L, Pekosz, Andrew, Bloch, Evan M, Hanley, Daniel, Casadevall, Arturo, Tobian, Aaron A R, Sullivan, David J

Get full text